Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-07
1998-07-07
Nutter, Nathan M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 34, 514 35, 514183, 514283, 514411, 514506, 514515, 514765, 514950, A61K 3816, A01N 4304
Patent
active
057768919
ABSTRACT:
The present invention comprises methods and compositions for reducing or eliminating multidrug resistance in cancers or certain infections by drug resistant microorganisms in patients. According to the method and composition of the present invention, a non-ionic amphipathic diester of fatty acids or a reverse poloxmer is administered to a patient in which a cancer or microorganism exhibits multidrug resistance to the chemotherapeutic agent. The method and composition of the present invention may be employed with particular efficacy where multidrug resistance to any chemotherapeutic agent has been conferred upon a cancer.
REFERENCES:
patent: 3919411 (1975-11-01), Glass et al.
patent: 4282054 (1981-08-01), Mattor et al.
patent: 4557934 (1985-12-01), Cooper
patent: 4563351 (1986-01-01), Caslavsky et al.
patent: 4634732 (1987-01-01), Miller et al.
patent: 4753965 (1988-06-01), Stemerick et al.
patent: 4803081 (1989-02-01), Falk et al.
patent: 4863968 (1989-09-01), Edwards et al.
patent: 4889525 (1989-12-01), Yuhas et al.
patent: 4904697 (1990-02-01), Sunkara et al.
patent: 4923862 (1990-05-01), Hirota
patent: 4978332 (1990-12-01), Luck et al.
patent: 4978622 (1990-12-01), Mishell et al.
patent: 4996321 (1991-02-01), Baldwin
patent: 5108989 (1992-04-01), Amento et al.
Paradis, R. et al., "Use of pluronic micelles to overcome multidrug resistance," International Journal of Oncology, 5:1305-1308 (1994).
Pages, M. et al., "Elimination of P-170 Mediated Multi-Drug Resistance by Solubilization in Pluronic Micelles," Database BIOSIS, Philadelphia, PA (1992) and Proc. Am. Assoc. Cancer Res. Ann. Meet., 33: 552 (1992).
Buckingham, L.E. et al., "Comparison of Solutol HS 15, Cremophor EL and novel ethoxylated fatty acid surfactants as multidrug resistance modification agents," Int. J. Cancer, 62(4):436-442 (1995).
Chong, A.S. et al. "Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cells," Cancer Immunol. Immunother., 36(2):133-139 (1993).
Coon, et al., "SOLUTOL.RTM. HS15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance," Cancer Research, vol. 15, pp. 897-902 (Feb. 1991).
Coon, J.S., et al., "Survey of surfactants for reversing multidrug resistance," Proc. Am. Assoc. Cancer Res. Annu. Meet., vol. 33, p. 484 (Mar. 1992).
Woodcock, D., et al., "Reversal of the Multidrug Resistance Phenotype with Cremophor EL, a Common Vehicle for Water-insoluble Vitamins and Drugs," Cancer Research, vol. 50, pp. 4199-4230 (Jul. 15, 1990).
Riehm, H., et al., "Potentiation of Drug Effect by Tween 80 in Chinese Hamster Cells Resistant to Actinomycin D. and Daunomycin," Cancer Research, vol. 32, pp. 1195-1200(Jun. 1972).
Woodcock, D., et al., "Reversal of Multidrug resistance by surfactants," Br. J. Cancer, vol. 66, pp. 62-88 (Jul. 1992).
Endicott, J., et al., "The Biochemistry of P-Glycoprotein-Mediated Multidrug Resistance," Annu. Rev. Biochem., vol. 58, pp. 137-171 (1989).
Pastan, I., et al., "Molecular Manipulations of the Multidrug Transporter: A New Role for Transgenic Mice," FASEB Journal, vol. 5, pp. 2523-2528 (1991).
Drug & Market Development, "Multidrug Resistance in Cancer Therapy," Drug & Market Development, vol. 3, No. 1/2 (Jul. 6, 1992).
Cornwell, M., et al., "Membrane Vesicles from Multidrug-Resistant Human Cancer Cells Contain a Specific 150-to 170-kDA Protein Detected by Photoaffinity Labeling," Proc. Natl. Acad. Sci., USA, vol. 83, pp. 3847-3850 (1986).
Sehested, M., et al., "Relationship of VP-16 to the Classical Multidrug Resistance Phenotype," Cancer Research, vol. 52, pp. 2874-2879 (May 15, 1992).
Chen, C., et al., "Internal Duplication and Homology with Bacterial Transport Proteins in the MDR1 (P-Glycoprotein) Gene from Multidrug-Resistant Human Cells," Cell, vol. 47, pp. 381-389 (1986).
Kartner, N., et al., "Detection of P-Glycoprotein in Mutidrug-Resistant Cell Lines by Monoclonal Antibodies," Nature, vol. 316, pp. 820-823 (1985).
Beck, W., et al., "Altered Surface Membrane Glycoproteins in Vinca Alkoloid-resistant Human Leukemic Lymphoblasts," Cancer Research, vol. 39, pp. 2070-2076 (1979).
Gerlack, J., et al., "Homology Between P-Glycoprotein and a Bacterial Haemolysin Transport Protein Suggess a Model for Multidrug Resistant," Nature, vol. 324, pp. 485-489 (1986).
Willingham, M., et al., "Immunocytochemical Localization of P170 at the Plasma Membrane of Multidrug-Resistant Human Cells," Journal of Histochemistry and Cytochemistry, vol. 35, No. 12, pp. 1451-1456 (1987).
Hamada, H., et al., "Purification of the 170-to 180-Kilodalton Membrane Glycoprotein Associated with Multidrug Resistance," Journal of Biological Chemistry, vol. 263, No. 3, pp. 1454-1458 (1988).
Juliano, R., et al., "A Surface Glycoprotein Modulating Drug Permeability in Chinese Hamster Ovary Cell Mutants," Biochemica et Biophysica Acta, vol. 455, pp. 152-162 (1976).
Shen, D., et al., "Multiple Drug-Resistant Human KB Carcinoma Cells Independently Selected for High-Level Resistance to Colchicine, Adriamycin, or Vinblastine Show Changes in Expression of Specific Proteins," Journal of Biological Chemistry, vol. 261, No. 17, pp. 7762-7770 (1986).
Dordal, M., et al., "Kinetic Analysis of P-Glycoprotein-Mediated Doxorubicin Efflux," The Journal of Pharmacology and Experimental Theerapeutics, vol. 263, pp. 752-766 (Nov. 1992).
Goldstein, L., et al., "Expression of a Multidrug Resistance Gene in Human Cancers," Journal of the National Cancer Institute, vol. 81, No. 2, pp. 116-124 (1989).
Gros, P., et al., "Mammalian Multidrug Resistance Gene: Complete cDNA Sequence Indicates Strong Homology to Bacterial Transport Proteins," Cell, vol. 47, pp. 371-380 (1986).
Roninson, I., et al., Amplification of Specific DNA Sequences Correlates with Multi-drug Resistance in Chinese Hamster Cells, Nature, vol. 309, pp. 626-628 (1984).
Thorgeirsson, S., et al., "Expression of the Multidrug-Resistant Gene in Hepatocarcinogenesis and Regenerating Rat Liver," Science, vol. 236, pp. 1120-1122 (1987).
Scotto, K., et al., "Amplifications and Expression of Genes Associated with Multidrug Resistance in Mammalian Cells," Science, vol. 232, pp. 751-755 (May 9, 1986).
Van der Bliek, A., et al., "Overexpression and Amplification of Five Genes in a Multidrug-Resistant Chinese Hamster Ovary Cell Line," Molecular and Cellular Biology, vol. 6, No. 5, pp. 1671-1678 (1986).
Gros, P., et al., "Isolation and Expression of a Complementary DNA that Confers Multidrug Resistance," Nature, vol. 323, pp. 728-732 (1986).
Fojo, A., et al., "Intrinsic Drug Resistance in Human Kidney Cancer is Associated with Expression of a Human Multidrug-Resistance Gene," Journal of Clinical Oncology, vol. 5, No. 12, pp. 1922-1927 (1987).
Roninson, I., et al., "Isolation of Human mdr DNA Sequences Amplified in Multidrug-Resistant KB Carcinoma Cells," Proc. Natl. Acad. Sci., USA, vol. 83, pp. 4538-4542 (1986).
Fojo, A., et al., "Amplification of DNA Sequences in Human Multidrug-Resistant KB Carcinoma Cells," Proc. Natl. Acad. Sci. USA, vol. 82, pp. 7661-7665 (1985).
Ueda, K., et al., "The Human Multidrug Resistant (mdrl) Gene," Journal of Biological Chemistryvol. 262, pp. 505-508 (1987).
Arceci, R., et al., "The Gene Encoding Multidrug Resistance is Induced and Expressed at high Levels During Pregnancy in the Secretory Epithelium of the Uterus," Proc. Natl., Acad. Sci., USA, vol. 85, pp. 4350-4354 (1988).
Fojo, A., et al., "Expression of a Multidrug-resistance Gene in Human Tumors and Tissues," Proc. Natl. Acad. Sci., USA, vol. 84, pp. 265-269 (1987).
Mukhopadhyay, T., et al., "Expression of the mdr (P-Glycoprotein) Gene in Chinese Hamster Digestive Tracts," Journal of the National Cancer Institute, vol. 80, No. 4, pp. 269-275 (1988).
Shen, D., et al., "Human Multidrug-Resistant Cell Lines: Increased mdrl Expression Can Precede Gene Amplification," Science, vol. 232, pp. 643-645 (1986).
Fairchild, C., et al., "Carcinogen-Induced mdr Overexpression is Associated with Xenobiotic Resistance in Rat Preneoplastic Liver Nodules and Hepatocellular Carcinomas," Proc. Natl. Acad. Sci., USA, vol. 84, pp. 7701-770
Balasubramanian Mannarsamy
Coon John S.
Emanuele R. Martin
Shah Himanshu
Nutter Nathan M.
Rush Prebyterian-St. Luke Medical Center
LandOfFree
Compositions for reducing multidrug resistance does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for reducing multidrug resistance, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for reducing multidrug resistance will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1205868